A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group.
作者： R C Coombes , P S Schein , C E Chilvers , J Wils , G Beretta
DOI: 10.1200/JCO.1990.8.8.1362
关键词:
摘要: Three hundred fifteen patients with operable gastric cancer were randomized to receive fluorouracil, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and mitomycin (FAM) or no adjuvant treatment between September 1981 July 1984. After excluding ineligible patients, 281 are included in this analysis. Treatment was moderately well tolerated by the majority of common side effects being nausea vomiting (58%) alopecia (57%). possible treatment-related deaths seen, all due cardiac failure. At median follow-up 68 months, 164 have died, 73 treated arm 91 control arm. There significant difference disease-free overall survival two arms study (P = 0.21). is some evidence that more advanced carcinoma (T3-T4) derived benefit from 0.04). The interpretation finding must take into account subgroups defined retrospectively, could, t...
elsevier.com
sci-hub.se 参考文章(9)
R. Jakesz, C. Dittrich, J. Funovics, F. Hofbauer, H. Rainer, G. Reiner, M. Schemper, R. Schiessel, M. Starlinger, The Effect of Adjuvant Chemotherapy in Gastric Carcinoma Is Dependent on Tumor Histology: 5- Year Results of a Prospective Randomized Trial Combined Modality Therapy of Gastrointestinal Tract Cancer. ,vol. 110, pp. 44- 51 ,(1988) , 10.1007/978-3-642-83293-2_6
M. Lise, D. Nitti, M. Buyse, G. Cartei, A. Fornasiero, J. Guimaraes dos Santos, N. Duez, Phase-III Clinical Trial of Adjuvant FAM2 (5-FU, Adriamycin and Mitomycin C) vs Control in Resectable Gastric Cancer: A Study of the EORTC Gastrointestinal Tract Cancer Cooperative Group Combined Modality Therapy of Gastrointestinal Tract Cancer. ,vol. 110, pp. 36- 43 ,(1988) , 10.1007/978-3-642-83293-2_5
Blake Cady, David A. Ramsden, Avrum Stein, Rodger C. Haggitt, Gastric cancer The American Journal of Surgery. ,vol. 133, pp. 423- 429 ,(1977) , 10.1016/0002-9610(77)90126-X
Michel Huguier, Jean-Pierre Destroyes, Christian Baschet, François Le Henand, Philippe-Francois Bernard, Gastric carcinoma treated by chemotherapy after resection: a controlled study. American Journal of Surgery. ,vol. 139, pp. 197- 199 ,(1980) , 10.1016/0002-9610(80)90253-6
R Peto, M C Pike, P Armitage, N E Breslow, D R Cox, S V Howard, N Mantel, K McPherson, J Peto, P G Smith, Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. British Journal of Cancer. ,vol. 35, pp. 1- 39 ,(1977) , 10.1038/BJC.1977.1
Takao Hattori, Kiyoshi Inokuchi, Tetsuo Taguchi, Osahiko Abe, Postoperative adjuvant chemotherapy for gastric cancer, the second report. Analysis of data on 2873 patients followed for five years. Surgery Today. ,vol. 16, pp. 175- 180 ,(1986) , 10.1007/BF02471090
John S Macdonald, Philip S Schein, Paul V Woolley, Tarilyn Smythe, Winston Ueno, Daniel Hoth, Frederick Smith, MICHEL BOIRON, CHRISTIAN GISSELBRECHT, RENE BRUNET, CLAUDE LAGARDE, None, 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric Cancer Annals of Internal Medicine. ,vol. 93, pp. 533- 536 ,(1980) , 10.7326/0003-4819-93-4-533
D. Oakes, D.R. Cox, Analysis of Survival Data ,(1984)
Wilson Rg, Hardcastle Jd, Blake, Gastric cancer: a controlled trial of adjuvant chemotherapy following gastrectomy. Clinical Oncology. ,vol. 7, pp. 13- 21 ,(1981)